Melanoma Clinical Trials in Dallas

Showing 81-100 of 236 trials

A Study to Investigate LYL845 in Adults With Solid Tumors

NCT05573035

This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).

MelanomaNon-small Cell Lung CancerColorectal Cancer

Lyell Immunopharma, Inc.39 participantsStarted Dec 2022

Sacramento, California, United States • Santa Monica, California, United States • Stanford, California, United States +15 more locations

TERMINATEDPhase 2< 1 mile

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6

NCT04830124

This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma

Cutaneous MelanomaMucosal Melanoma

Mural Oncology, Inc173 participantsStarted Sep 2021

La Jolla, California, United States • Los Angeles, California, United States • Jacksonville, Florida, United States +38 more locations

A Study to Investigate LYL845 in Adults With Solid Tumors

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6

Melanoma Trials in Other Cities

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

A Study of SEA-CD40 Given With Other Drugs in Cancers

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

MGC018 With or Without MGA012 in Advanced Solid Tumors

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes

Other Conditions in Dallas